Imaging for Screening, Prevention and Longevity

SEE EARLIER,
CARE BETTER.

Featuring leading international speakers.

UEMS/SEAFORMEC accreditation and Fenin validation have been requested.
Register here
5 and 6 November 2026
Auditorium, Hospital Universitario Ramón y Cajal. Madrid

Course directors:

Dr. Antonio Luna
Scientific Director, HT Médica
Dr. Javier Blázquez
Head of Radiology, Hospital Universitario Ramón y Cajal
Dra. Ana Villanueva
Abdominal and Pelvic CT Coordinator at HT Médica

WE INVITE YOU TO THIS COURSE

ACCESS THIS FREE RESOURCE USING THE FORM BELOW

Introduction

See earlier. Care better.

The 17th Advanced Medical Imaging Techniques Course – IMA 17 focuses on the growing role of medical imaging in screening, prevention, and longevity.

Over two days, national and international experts will explore how advanced imaging, biomarkers, artificial intelligence, and new risk models are helping us detect earlier, stratify risk more accurately, and move towards more personalised medicine.

A meeting designed to review the evidence, share experience, and discuss how to translate these advances into clinical practice.

  • Critically review the evidence, recommendations, benefits, potential harms and current controversies surrounding imaging-based screening in the general population and in risk-stratified groups.
  • Examine state-of-the-art MRI, CT and spectral CT, ultrasound and multimodality strategies for cancer, cardiovascular, neurovascular and neurodegenerative screening and early disease detection.
  • Understand how imaging can be integrated with clinical risk assessment, genomics, liquid biopsy (including circulating tumor cells and circulating tumour DNA and cell-free DNA), blood and urine biomarkers, artificial intelligence and quantitative/opportunistic imaging biomarkers to enable precision prevention.
  • Discuss practical implementation, including protocol optimisation, standardisation, actionable reporting, contrast use, management of incidental findings, follow-up pathways and health-system integration.
  • Explore emerging directions in preventive imaging and longevity medicine, including subclinical disease detection, longitudinal risk assessment and imaging for selection and monitoring of preventive or disease-modifying therapies.

IMA 17 is designed for professionals involved in screening, prevention, early detection, and precision medicine:

  • Radiology: Radiologists and radiology residents.
  • Clinical specialties: Oncology, cardiology, neurology, urology, gastroenterology, pulmonology, internal medicine, preventive medicine, genetics, primary care, and precision medicine.
  • Imaging and healthcare technology: Imaging technologists, medical physicists, bioengineers, and biomedical engineers.
  • Data and innovation: Data scientists, artificial intelligence specialists, and researchers.
  • Other healthcare professionals: Professionals involved in the design, implementation, or evaluation of screening and prevention programs.

November 5, 2026 Precision Cancer Prevention, Organ-Specific Cancer Screening, Cardiovascular Prevention, Whole-Body MRI and Neuroimaging

08:45 - 08:55h OPENING

  • 08:45 - 08:55h Welcome and Opening Remarks — Course Directors

08:55 - 09:45h PRECISION CANCER PREVENTION

  • 08:55 - 09:20h The Role of Imaging in Longevity and Precision Prevention — Where imaging fits alongside clinical risk assessment, laboratory biomarkers, genomics, functional testing and other screening tools; moving from detection to actionable prevention — Ángel Durántez — Clínica Neleva, Spain
  • 09:20 - 09:45h Beyond Imaging: Circulating Tumor Cells, Liquid Biopsy and Emerging Biomarkers for Cancer Screening and Interception — CTCs, circulating tumor DNA, cell-free DNA, epigenetic and molecular biomarkers, and their potential integration with imaging for early cancer detection and risk-adapted screening — María José Serrano — Liquid Biopsy and Cancer Interception Group, GENYO, Granada, Spain

09:45 - 10:40h BREAST CANCER SCREENING — IMAGING + PRECISION RISK

  • 09:45 - 10:10h Breast Cancer Screening: From Population-Based Mammography to Risk-Adapted Imaging — Breast density, individualised risk, MRI, abbreviated MRI and current controversies — Ana Rodríguez — HT Médica–Instituts Guirado, Barcelona; Breast Imaging Coordinator, HT Médica
  • 10:10 - 10:35h Beyond Imaging in Breast Cancer Risk Assessment and Screening: Genetics, Polygenic Risk and Emerging Blood Biomarkers — Integrating family history, germline genetics, polygenic risk, clinical factors and emerging circulating biomarkers into individualised screening and prevention strategies — María Alejandra Rezqallah Arón — Centro Médico Teknon / Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  • 10:35 - 10:40h Block Q&A and Discussion — All Faculty

10:40 - 11:10h Coffee Break

11:10 - 12:05h OTHER CANCER SCREENING

  • 11:10 - 11:35h Colorectal Cancer Screening: Where Does Imaging Fit? — Current strategies, CT colonography, indications, limitations and controversies — Stuart A. Taylor — University College London, UK
  • 11:35 - 12:00h Lung Cancer Screening with Low-Dose CT: Evidence, Risk-Based Selection and Emerging Imaging Biomarkers — Implementation, nodule management and future perspectives — Luis Gorospe — Hospital Universitario Ramón y Cajal, Madrid, Spain
  • 12:00 - 12:05h Block Q&A and Discussion — All Faculty

12:05 - 13:40h CARDIOVASCULAR SCREENING AND PRECISION PREVENTION

  • 12:05 - 12:30h Cardiac Imaging for Screening and Prevention: Who Should We Image and With Which Technique? — Echocardiography, coronary calcium, coronary CT angiography, cardiac MRI, vascular assessment and emerging CT/PCCT applications — José Luis Zamorano — Hospital Universitario Ramón y Cajal, Madrid, Spain
  • 12:30 - 12:55h Bridging Prospective Imaging Cohorts and Cardiovascular Prevention: Lessons from PESA, BioImage and REACT — Natural history of subclinical atherosclerosis, multiterritorial vascular imaging, risk reclassification and implications for precision prevention. — Inés García-Lunar — Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
  • 12:55 - 13:20h Coronary CT Angiography and CT-Derived FFR in Cardiovascular Screening: From Anatomic Detection to Functional Risk Stratification — Role of CCTA in detecting subclinical coronary atherosclerosis and the added value of CTA Plus / FFR-CT for functional assessment and risk-adapted management — Gorka Bastarrika — Clínica Universidad de Navarra, Pamplona, Spain
  • 13:20 - 13:35h What is MyoStrain and what is its clinical utility as a screening technique: our experience — Álvaro Arribas Marcos — Hospital Universitario Ramón y Cajal, Madrid, Spain
  • 13:35 - 13:40h Block Q&A and Discussion — All Faculty

13:40 - 14:40h Lunch

14:40 - 16:25h WHOLE-BODY MRI SCREENING

  • 14:40 - 15:05h Whole-Body MRI for Oncologic Screening: From High-Risk Populations to the Asymptomatic General Population — Evidence, indications, diagnostic performance, limitations and controversies — Antonio Luna — Scientific Director, HT Médica, Spain
  • 15:05 - 15:30h Optimising and Standardising Whole-Body MRI for Screening: Acquisition, DWI, ONCO-RADS and Reporting — Protocol design, diffusion-weighted imaging, reproducibility, acquisition time and standardisation of interpretation and reporting — Kai Vilanova — Clínica Girona, Girona, Spain
  • 15:30 - 15:55h Whole-Body MRI Screening in Clinical Practice: Lessons from Large-Scale Implementation — Real-world experience, patient selection, workflow, incidental findings and downstream management — Amar Patel — Prenuvo Medical Group. Virtual participation.
  • 15:55 - 16:20h MRI for Screening and Preventive Imaging: Faster, Quantitative and More Reproducible Examinations — Acceleration, quantitative MRI, reproducibility and scalable preventive imaging workflows — Javier Sánchez González — Philips Healthcare Iberia
  • 16:20 - 16:25h Block Q&A and Discussion — All Faculty

16:25 - 16:45h Coffee Break

16:45 - 19:00h NEUROIMAGING — POPULATION SCREENING, PREVENTION, NEURODEGENERATION AND EPILEPSY

  • 16:45 - 17:10h Dementia prediction using a large dataset of brain imaging linked to health data from the National Health Services (NHS) in Scotland — María Valdés Hernández — University of Edinburgh / Edinburgh Imaging, Edinburgh, UK. Virtual participation.
  • 17:10 - 17:35h The Role of Imaging in Neurovascular Prevention — Detection of silent cerebrovascular disease, vascular brain injury and small-vessel disease, and integration of cardiovascular and brain imaging for prevention — Marta Cortés-Canteli — Centro Nacional de Investigaciones Cardiovasculares (CNIC) / Centro de Neurociencias Cajal (CNC-CSIC), Madrid, Spain
  • 17:35 - 18:00h Imaging and Multimodal Biomarkers in Preclinical and Early Alzheimer’s Disease — Neuroimaging, genetics and fluid biomarkers for early detection, risk stratification and definition of therapeutic windows — Teresa Cabada Giadás — Head of Neuroradiology Section, Hospital Universitario de Navarra (HUN), Pamplona, Spain
  • 18:00 - 18:25h Disease-Modifying Therapies in Alzheimer’s Disease: Patient Selection, Biomarkers and Imaging Follow-up — Anti-amyloid therapies, biomarker-based eligibility, ARIA risk, MRI monitoring and multidisciplinary follow-up — Víctor Antonio Blanco Palmero — Memory Unit, Hospital Ruber Internacional; Memory Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
  • 18:25 - 18:50h MRI in Epilepsy: From Structural Imaging to Advanced Phenotyping — Optimized MRI protocols, subtle epileptogenic lesions and advanced imaging approaches — Juan Álvarez-Linera — Madrid, Spain
  • 18:50 - 19:00h Block Q&A and Discussion — All Faculty

November 6, 2026 Opportunistic Screening, Body Composition, Advanced Imaging and Prostate Cancer Screening

Special Session: Opportunistic Screening, Body Composition and Advanced Imaging

08:45 - 11:45h OPPORTUNISTIC SCREENING, BODY COMPOSITION AND ADVANCED IMAGING

  • 08:45 - 09:10h Opportunistic CT Biomarkers: Fat, Calcification, Bone and Muscle — Visceral and subcutaneous adipose tissue, vascular calcification, osteoporosis, sarcopenia and muscle quality — Matthew Lee — University of Wisconsin–Madison, USA
  • 09:10 - 09:35h Spectral CT for Prevention: One Scan, More Answers. — Nicolás Almeida — Hospital Universitario Nuestra Señora del Rosario, Madrid, Spain
  • 09:35 - 10:00h Beyond Traditional Biomarkers: CT Biological Age and AI-Driven Risk Prediction — Biological age, cardiovascular risk, fracture prediction and explainable AI — Matthew Lee — University of Wisconsin–Madison, USA
  • 10:00 - 10:25h Management of Incidental Findings in Imaging-Based Screening — Classification, communication, follow-up strategies, risk-adapted management and minimizing unnecessary diagnostic cascades — Ana Villanueva — Body CT Coordinator, HT Médica, Madrid, Spain
  • 10:25 - 10:50h Actionable Imaging Biomarkers: Team Science for Opportunistic Imaging Across a Health System — Development, validation, implementation and scalability of opportunistic biomarkers — Matthew Lee — University of Wisconsin–Madison, USA
  • 10:50 - 11:15h Whole-Body MRI in Children with Tumour Predisposition — Emilio J. Inarejos Clemente — Hospital Sant Joan de Déu, Barcelona, Spain
  • 11:15 - 11:30h AI applied to routine imaging: assessment of osteoporosis, abdominal volumetry and breast arterial calcification — Patrick Kara-Schmidt — Floy, Germany
  • 11:30 - 11:45h Block Q&A and Discussion — All Faculty

11:45 - 12:15h Coffee Break

12:15 - 14:15h PROSTATE CANCER SCREENING — MRI + MULTIMODAL RISK

  • 12:15 - 12:40h Prostate MRI as a Screening Tool: PRISM Recommendations and the Emerging “MRI-first” Paradigm — Risk-adapted screening and the role of MRI in modern diagnostic pathways — Sadhna Verma — University of Cincinnati, USA
  • 12:40 - 13:05h Beyond MRI: The Future of Risk-Adapted Prostate Cancer Screening — PSA-based strategies, serum and urine biomarkers, germline and polygenic risk, risk calculators and integration with MRI in population screening programs — Juan Ignacio Martínez-Salamanca — LYX Urología, Madrid, Spain
  • 13:05 - 13:30h PI-RADS 2027: The New Version — What’s Changing and Implications for Screening and Diagnosis — Sadhna Verma — University of Cincinnati, USA
  • 13:30 - 13:45h The Role of AI in Prostate Cancer Screening and Diagnosis — David Bazaga — VP of Product · Quibim
  • 13:45 - 14:00h Block Q&A and Discussion — All Faculty
  • 14:00 - 14:15h Closing Remarks — Course Directors